Last month, C4 Therapeutics dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, combined with ...
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy Adult subjects with ...
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage ...
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 ...
Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial. The ongoing PROCEADE-CRC-01 study (NCT05464030) is investigating the dose, ...
(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 oral ...
STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results